Physician profile
Alan N Oki
NPI 1982657268
$12,598.38
in general payments reported to CMS, 2019-2025
23 companies · $1,156 in 2025
The $1,156 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,552 · 2020: $1,060 · 2021: $542 · 2022: $2,036 · 2023: $2,805 · 2024: $2,447 · 2025: $1,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,397 · Education: $11.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,396.85 |
| Education | $11.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,249.30 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $1,775.29 | 2019-2025 | |
| Pfizer INC. | $1,147.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $924.18 | 2019-2024 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $900.42 | 2019-2024 | |
| Lilly USA, LLC | $869.35 | 2019-2024 | Taltz, Olumiant |
| Aurinia Pharma U.S., INC. | $674.82 | 2021-2024 | Lupkynis |
| Ucb, INC. | $581.39 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $572.15 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $425.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $399.16 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $325.59 | 2023-2025 | Saphnelo |
| Janssen Biotech, INC. | $140.51 | 2019-2025 | Simponi Aria, Tremfya |
| Genentech USA, INC. | $121.89 | 2019 | |
| Radius Health, INC. | $116.81 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $74.94 | 2019 | |
| Sobi, INC | $64.32 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $54.10 | 2023 | Strensiq |
| Biohaven Pharmaceuticals, INC. | $48.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.20 | 2019-2024 | Orencia |
| Celgene Corporation | $41.31 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $32.20 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Oki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.